Chris JacobsSell
Assembly biosciences, Inc. · Transaction Jan 4, 2021 · Filed Feb 17, 2021 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · ASMB
0.00% · $0.0000 · Vol Not reported
Market closed · last close shown
Assembly Biosciences Inc
Biotechnology
$22.82
Follow $ASMB
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $ASMB by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredThu Oct 8 · last completed session · Pre-market · regular session opens 9:30 ET · ASMB
MethodologyASMB
Assembly Biosciences Inc
Thu Oct 8 · last completed session · Pre-market · regular session opens 9:30 ET
Highest qualified
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
76/ 100
Veridion Score
Highest qualified · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Thu Oct 8 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is ASMB moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Assembly Biosciences Inc
PHARMACEUTICAL PREPARATIONSListed since
2010
Employees
73
Country
US
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$22.82
Last session
Day high
$22.82
Last session
Day low
$22.82
Last session
Previous close
$22.82
52W high
$38.50
-40.73% from high
52W low
$22.18
4% of range
Market cap
$464.6M
EPS
$-0.1626
Beta
0.87
Shares out
20.4M
Avg volume
347.8K
VWAP
$22.82
Last session
Price history computed in-house
1W
+1.24%
1M
-30.57%
3M
-16.72%
1Y
-14.91%
YTD
-32.90%
SMA 50 $28.64 · below
SMA 200 $28.15 · below
52W position 4%
ASMB overview
Related filings and maps
Public disclosures
Congress activity in ASMB
1 filers · 1 buys · 1 sells (0 labeled S (partial)) · Dec 28, 2020 to Jan 4, 2021 · House 2 / Senate 0
All available history · Latest 2 of 2 lines · Read 2026-10-09T13:05:26.639Z
Official filing ↗
Chris JacobsBuy
Assembly biosciences, Inc. · Transaction Dec 28, 2020 · Filed Feb 10, 2021 · $1,001 to $15,000
Federal contracts
ASMB contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ASMB in this window.
Lobbying spend
ASMB lobbying filings, year to date.
Registered lobbying filings matched to Assembly Biosciences Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ASMB in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for ASMB.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.